{"organizations": [], "uuid": "cba2d8a23ce30d9e9e5db51d9cb54c75c9c795a1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-bristol-myers-says-fda-approves-op/brief-bristol-myers-says-fda-approves-opdivo-yervoy-combo-for-treating-patients-with-renal-cell-carcinoma-idUSASC09VZ4", "country": "US", "domain_rank": 408, "title": "BRIEF-Bristol-Myers Says FDA Approves Opdivo + Yervoy Combo For Treating Patients With Renal Cell Carcinoma", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-16T22:42:00.000+03:00", "replies_count": 0, "uuid": "cba2d8a23ce30d9e9e5db51d9cb54c75c9c795a1"}, "author": "", "url": "https://www.reuters.com/article/brief-bristol-myers-says-fda-approves-op/brief-bristol-myers-says-fda-approves-opdivo-yervoy-combo-for-treating-patients-with-renal-cell-carcinoma-idUSASC09VZ4", "ord_in_thread": 0, "title": "BRIEF-Bristol-Myers Says FDA Approves Opdivo + Yervoy Combo For Treating Patients With Renal Cell Carcinoma", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "renal cell carcinoma reuters", "sentiment": "none"}, {"name": "squibb co", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 16, 2018 / 7:42 PM / Updated 19 minutes ago BRIEF-Bristol-Myers Says FDA Approves Opdivo + Yervoy Combo For Treating Patients With Renal Cell Carcinoma Reuters Staff 1 Min Read \nApril 16 (Reuters) - Bristol-Myers Squibb Co: \n* U.S. FOOD AND DRUG ADMINISTRATION APPROVES OPDIVO® (NIVOLUMAB) + YERVOY® (IPILIMUMAB) COMBINATION AS FIRST-LINE TREATMENT FOR PATIENTS WITH INTERMEDIATE- AND POOR-RISK ADVANCED RENAL CELL CARCINOMA \n* BRISTOL-MYERS SQUIBB - IN PHASE 3 CHECKMATE -214 CLINICAL TRIAL, OPDIVO + YERVOY COMBINATION DEMONSTRATED A SIGNIFICANT INCREASE IN OVERALL SURVIVAL \n* BRISTOL-MYERS SQUIBB - IN PHASE 3 CHECKMATE -214 TRIAL, OPDIVO + YERVOY ALSO DELIVERED DURABLE RESPONSES, WITH HIGHER OBJECTIVE RESPONSE RATE VERSUS SUNITINIB Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-16T22:42:00.000+03:00", "crawled": "2018-04-16T23:11:11.009+03:00", "highlightTitle": ""}